Form 4: Revolution Medicines Executive Stephen Michael Kelsey Reports Stock Option Exercises and Sales

Stephen Michael Kelsey, a key executive at Revolution Medicines, executed stock option exercises and subsequent sales of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On June 24 and 25, 2024, Stephen Michael Kelsey, President of Research and Development at Revolution Medicines, exercised stock options to purchase common stock at a price of $4.09 per share.
• Following the exercise of these options, Kelsey sold shares of common stock at an average price of approximately $39 per share.
• These transactions were conducted under a pre-existing 10b5-1 trading plan adopted on March 15, 2024.
• The reported transactions resulted in a net decrease in the number of common stock shares directly held by Kelsey, but he still holds 269,073 shares.
• Kelsey also holds 89,999 stock options after the reported transactions.

Sentiment

Score: 6

Explanation: The sentiment is neutral. It reflects standard executive compensation activity (option exercise and stock sale) under a pre-arranged plan. There is no indication of unusual or concerning activity.

Positives

• The use of a 10b5-1 trading plan suggests that these transactions were pre-planned and not based on insider information.

Industry Context

Form 4 filings are standard disclosures required by the SEC when company insiders, such as officers and directors, trade their company's stock. These filings provide transparency into insider transactions and are closely watched by investors.

Comparison to Industry Standards

• Executive stock option exercises and sales are common in publicly traded companies, particularly in the biotechnology sector.
• The use of a 10b5-1 trading plan is a standard practice to avoid accusations of insider trading.
• The reported transactions are similar to those seen at other comparable companies where executives periodically exercise options and sell shares for personal financial management.

Stakeholder Impact

• The transactions may have a minor impact on shareholders due to the change in ownership, but the use of a 10b5-1 plan mitigates concerns about insider trading.
• Employees may view the transactions as a positive sign of executive confidence in the company, but this is dependent on the broader context of the company's performance.

Key Dates